Compare
Regencell Bioscience Holdings Ltd vs Charlie's Holdings, Inc. vs Synergy CHC Corp. vs Cyanotech Corp
| Latest fiscal year | Regencell Bioscience Holdings Ltd RGC | Charlie's Holdings, Inc. CHUC | Synergy CHC Corp. SNYRQ | Cyanotech Corp CYANLast annual report: year ended 2025-03-31 |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-03-31 |
| Revenue | n/a | $20.92M | $30.38M | $24.21M |
| Revenue growth (YoY) | n/a | +169.4% | -12.8% | +5.0% |
| Gross margin | n/a | 27.0% | 66.8% | 28.4% |
| Operating margin | n/a | -10.4% | -27.8% | -10.4% |
| Net margin | n/a | 21.5% | -40.6% | -13.2% |
| Net income | -$11.70M | $4.50M | -$12.34M | -$3.20M |
| EPS (Diluted) | -$2.37 | $0.02 | -$1.27 | n/a |
| Operating cash flow | -$7.70M | -$5.78M | -$2.59M | -$1.19M |
| Free cash flow | n/a | -$5.80M | n/a | n/a |
| Cash & equivalents | n/a | n/a | $2.62M | $257.0K |
| Total assets | $14.73M | $11.56M | $10.16M | $23.49M |
| Total liabilities | $1.38M | $8.14M | $33.29M | $14.61M |
| Shareholders' equity | $13.35M | $3.42M | -$23.13M | $8.88M |
| Return on year-end equity | -87.7% | 131.4% | n/a | -36.1% |
| Shares outstanding | n/a | 270.65M | 11.30M | 7.20M |
Revenue, most recent five fiscal years
| Fiscal year | Regencell Bioscience Holdings Ltd | Charlie's Holdings, Inc. | Synergy CHC Corp. | Cyanotech Corp |
|---|---|---|---|---|
| Latest | n/a | $20.92M Ended 2025-12-31 | $30.38M Ended 2025-12-31 | $24.21M Ended 2025-03-31 |
| 1 year earlier | n/a | $7.76M Ended 2024-12-31 | $34.83M Ended 2024-12-31 | $23.07M Ended 2024-03-31 |
| 2 years earlier | n/a | $16.25M Ended 2023-12-31 | $42.78M Ended 2023-12-31 | $23.18M Ended 2023-03-31 |
| 3 years earlier | n/a | $26.42M Ended 2022-12-31 | n/a | $35.97M Ended 2022-03-31 |
| 4 years earlier | n/a | $21.50M Ended 2021-12-31 | n/a | $32.34M Ended 2021-03-31 |